Immutep Limited (ASX:IMM)


right-arrow Created with Sketch. -0.02 (-3.92%)
MCAP $418.3M
Last trade 16.10pm 26/11/2021 20mins delayed

Latest Announcements

26/11/2021IMMImmutep Limited
26/11/2021IMMImmutep Limited
26/11/2021IMMImmutep Limited
19/11/2021 Price SensitivePSIMMImmutep Limited
17/11/2021IMMImmutep Limited
17/11/2021 Price SensitivePSIMMImmutep Limited
16/11/2021IMMImmutep Limited
15/11/2021 Price SensitivePSIMMImmutep Limited

Company Overview

Immutep Limited is an Australia-based biotechnology company. The Company is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The Company has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.

IMM in the news

Immutep (IMM) completes recruitment for its phase II study for non-small cell…
Immutep (IMM) says its final trial results have given it confidence that…
Immutep (IMM) is granted a new patent by the Chinese Patent Office…
Shares in Immutep (IMM) open green after the company announced positive feedback…

Search Previous Announcements